Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.37 |
| ▸ | KDM5A | P29375 | 1/20 | 0.36 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.36 |
| ▸ | CCKBR | P32239 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6666007 | 0.91 | TRPV1 (0.39) | TRPV1 | |
| SCHEMBL6681850 | 0.90 | HDAC2 (0.42) | TRPV1HDAC2HDAC8HDAC6 | |
| SCHEMBL6685148 | 0.90 | TSHR (0.43) | CCKBR | |
| SCHEMBL6665845 | 0.85 | CCKBR (0.41) | CCKBR | |
| SCHEMBL6680500 | 0.84 | MAPT (0.47) | HDAC8HDAC6 | |
| SCHEMBL6678743 | 0.82 | RXRA (0.43) | CCKBR | |
| SCHEMBL6665695 | 0.82 | NR4A2 (0.43) | KDM5AKDM5B | |
| SCHEMBL6683144 | 0.81 | MEN1 (0.43) | — | |
| SCHEMBL6685985 | 0.81 | MAPT (0.51) | — | |
| SCHEMBL6835278 | 0.78 | KDM5A (0.35) | KDM5AKDM5B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040043985-A1 | 6,6-Fused heteroaryl derivatives as matrix metalloproteinase inhibitors | HICKS JAMES LESTER (US) | 2004-03-04 | — | — | US | disclosed |
| WO-2004014388-A1 | 6,6-FUSED HETEROARYL DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040043985-A1 | 6,6-Fused heteroaryl derivatives as matrix metalloproteinase inhibitors | MMP13, MMP26, MMP9 | TRPV1 3379/4885KDM5A 751/4885KDM5B 556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.